05.16.23 -- Increase Drug Development Efficiency Using Nanotechnology

Nanoform's CEO, Professor Edward Hæggström, and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca — a long term partner of Nanoform — discuss the potential of nanoscale medicines and delivery devices to benefit patients.

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Explore new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.

The low-hanging fruit of drug development — simple compounds — have mainly been used up, prompting companies to focus on more complex molecules. Yet most of these exhibit solubility and bioavailability challenges. Discover how nanoforming drug particles to below 100 nm could help.